# Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects

> **NCT00664430** · PHASE4 · TERMINATED · sponsor: **Abbott** · enrollment: 13 (actual)

## Conditions studied

- Secondary Hyperparathyroidism
- Dialysis

## Interventions

- **DRUG:** Calcitriol
- **DRUG:** Paricalcitol

## Key facts

- **NCT ID:** NCT00664430
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-01
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Low enrollment rate
- **Last updated:** 2012-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00664430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00664430, "Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00664430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*